Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

[1]  F. Zhan,et al.  Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts , 2008, Leukemia.

[2]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[3]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[4]  O. Sezer,et al.  Bortezomib inhibits human osteoclastogenesis , 2007, Leukemia.

[5]  M. Dimopoulos,et al.  Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma , 2006, British journal of haematology.

[6]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[7]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[8]  M. Abe,et al.  BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma , 2006, Leukemia.

[9]  A. Donnenberg,et al.  Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. , 2005, Blood.

[10]  M. Dimopoulos,et al.  The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio , 2005, Leukemia.

[11]  D. Esseltine,et al.  Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma , 2005, British journal of haematology.

[12]  V. Pantesco,et al.  The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. , 2005, Blood.

[13]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[14]  D. Esseltine,et al.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.

[15]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone , 2003 .

[16]  N. Callander,et al.  And Growth of Myeloma Cells Il-3 Expression by Myeloma Cells Increases Both Osteoclast Formation , 2022 .

[17]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[18]  L. To,et al.  Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. , 2003, Cancer research.

[19]  J. Goldman,et al.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. , 2003, Blood.

[20]  Paul J. Williams,et al.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. , 2003, Blood.

[21]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[22]  B. Dörken,et al.  Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. , 2003, Blood.

[23]  L. Hofbauer,et al.  RANK ligand and osteoprotegerin in myeloma bone disease. , 2003, Blood.

[24]  P. Croucher,et al.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.

[25]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[26]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[27]  K. Moriyama,et al.  Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma , 2002 .

[28]  G. Giannelli,et al.  Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. , 2002, Journal of cell science.

[29]  P. Richardson,et al.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.

[30]  N. Callander,et al.  Myeloma bone disease. , 2001, Seminars in hematology.

[31]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[32]  I. James,et al.  Biosynthesis and processing of cathepsin K in cultured human osteoclasts. , 2001, Bone.

[33]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[34]  J. Tschopp,et al.  APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth , 1998, The Journal of experimental medicine.

[35]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[36]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[37]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[38]  E. Wagner,et al.  Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.

[39]  K. Moriyama,et al.  Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. , 2002, Blood.

[40]  Z. Lee,et al.  The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. , 2002, Bone.

[41]  J. Moake,et al.  Immunocytochemistry reveals RANKL expression of myeloma cells , 2002 .

[42]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[43]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.